Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood test showdown: which marker best spots ventilator pneumonia?

NCT ID NCT07696897

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study compares two blood tests—procalcitonin and serum zinc—to see which more accurately diagnoses ventilator-associated pneumonia (VAP) in adult ICU patients. VAP is a common and serious infection in people on breathing machines, and early diagnosis is difficult. The trial will measure how well each test identifies the infection in 84 patients, using standard diagnostic criteria as the reference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If one biomarker proves more accurate, it could lead to faster, more reliable diagnosis of ventilator-associated pneumonia in ICU patients.
What could go wrong
This is a small, single-center observational study. Results may not apply to all ICU populations, and neither biomarker may prove clearly superior.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 84 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of adult patients aged 18 to 70 years admitted to the Intensive Care Unit of Sohag University Hospital who are receiving invasive mechanical ventilation for at least 48 hours and develop clinical suspicion of ventilator-associated pneumonia (VAP). Eligible participants will be enrolled consecutively and evaluated using clinical, radiological, microbiological, and laboratory criteria, including serum procalcitonin and serum zinc measurements.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Age 18 to 70 years. * Adult patients admitted to the Intensive Care Unit. * Receiving invasive mechanical ventilation for at least 48 hours. * Clinical suspicion of ventilator-associated pneumonia (VAP). * New or progressive pulmonary infiltrate on chest imaging. * At least two of the following: * Fever \>38°C or hypothermia \<36°C. * Leukocytosis (\>12,000/mm³) or leukopenia (\<4,000/mm³). * Purulent tracheal secretions. * Worsening oxygenation or increased ventilatory requirements. * Written informed consent obtained from the patient or legally authorized representative. Exclusion Criteria: * \- Age less than 18 years or greater than 70 years. * Known chronic liver disease. * End-stage renal disease requiring dialysis. * Immunocompromised patients (including HIV infection, chemotherapy, organ transplantation, or long-term immunosuppressive therapy). * Current zinc supplementation or known disorders of zinc metabolism. * Hematologic malignancies. * Autoimmune diseases requiring immunosuppressive treatment. * Active non-pulmonary bacterial infection requiring systemic antibiotic therapy. * Chronic inflammatory diseases that may affect serum zinc levels. * Pregnancy. * Refusal or inability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ventilator acquired pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Pneumonia, Ventilator-Associated

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sohag University Hospital

    Sohag, Sohag Governorate, 82524, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.